Trial Profile
Intrathecal Rituximab in Progressive Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Rituximab (Primary) ; Methylprednisolone
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms EFFRITE
- 02 Oct 2019 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 1 Sep 2017 to 7 Sep 2019.
- 16 Apr 2019 Status changed from recruiting to active, no longer recruiting.